SugarCone Biotech

MARCH 24, 2025

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. The blueprint reveals the structure of a productive T cell immune synapse cell surface and the proteins involved (Figure 1).

Immune Response 67

Immune Response Therapies Treatment Disease 67

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 106

Immune Response Laboratories DNA Virus 106

Broad Institute

JULY 11, 2024

Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. This immune response relies on the expression of a gene called cGAS , which produces part of a protein that detects retroviruses.

Treatment 72

Treatment Immune Response Drugs Virus 72

Drug Target Review

FEBRUARY 9, 2024

Additionally, ADSCs possess immunomodulatory properties, enabling them to modulate immune responses and promote tissue healing. Moreover, their immunomodulatory properties make them valuable assets in managing autoimmune diseases by suppressing aberrant immune responses.

Therapies 106

Therapies Immune Response Clinical Trials Treatment 106

Chemical Biology and Drug Design

JANUARY 29, 2024

Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation. Abstract The secreted phospholipase A 2 (sPLA 2 ) family of enzymes hydrolyzes glycerophospholipid substrates at the sn -2 position of the acyl ester bond.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

Drug Target Review

JUNE 9, 2023

This research has resulted in the first TCR-based therapeutic product candidate from the partnership to advance into clinical development. Looking ahead, Genentech has responsibility for clinical, regulatory and commercialisation efforts for any T-cell therapy product candidate.

Treatment 106

Treatment Packaging Clinical Research Therapies 106

PLOS: DNA Science

FEBRUARY 8, 2024

The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them. Beef production Add a gene conferring a short, slick coat that enables cattle to tolerate heat. But will it, can it, improve upon nature?

Immune Response 97

Immune Response DNA Engineering Virus 97

The Pharma Data

APRIL 15, 2022

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

DrugBank

MARCH 12, 2025

Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. This process triggers a robust immune response, enabling the immune system to recognize and attack cancer cells. Another challenge is the potential for unintended immune responses.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

DECEMBER 8, 2020

With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease and its Phase 2 Study to assess activation of anti-cancer immune response in colon cancer. “We

Immune Response 52

Immune Response Clinical Trials Disease Trials 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 17, 2020

In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation, the company said. “At

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. S-Trimer is intended to be adjuvanted.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

DrugBank

MAY 15, 2024

Another promising avenue is the use of technologies like RNA interference and gene editing, which allow scientists to turn off the production of certain proteins altogether. These methods could bypass the need to directly target these proteins with traditional drugs.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Conversations in Drug Development Trends

JUNE 21, 2024

Its primary challenges include: Production Delays : The time-intensive process of expanding TILs to therapeutic quantities poses logistical hurdles. Response Rates : To date, approximately 30% of patients are achieving objective responses, indicating considerable room for improvement.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Agency IQ

APRIL 12, 2024

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?

Production 40

Production FDA Therapies Biochemical Assays 40

The Pharma Data

OCTOBER 23, 2020

In this week’s update, Pharma IQ share updates from WHO’s solidarity clinical trial and a new treatment option in Europe to help clinicians receive a better understand the Covid-19 patient immune response. WHO concludes subcutaneous treatment is ineffective in hospitalized Covid-19 patients. Source link.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Premier Consulting Blog

APRIL 18, 2024

This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product. However, for cell and gene therapy products, the nonclinical program needs to identify a clinical dose that is likely both safe AND efficacious.

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

The Pharma Data

DECEMBER 23, 2020

Inotrem’s Phase IIa clinical trial, which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients. PARIS–( BUSINESS WIRE )– Inotrem S.A., Marc Derive. www.inotrem.com.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

The presence of serum antibodies against an infectious agent may be an indicator of immunity against said agent. About 20/20’s Pandemic Response: 20/20 currently provides an array of COVID-19 testing solutions including viral tests based on PCR, rapid antibody tests authorized for use at the point-of-care, and rapid antigen tests.

Vaccine 52

Vaccine Immune Response Pharmacy Production 52

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Engineering 52

The Pharma Data

AUGUST 16, 2021

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors. KSQ is also eligible to receive tiered royalties on net sales of each approved product.

Therapies 52

Therapies Immune Response Research Engineering 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. and its affiliate NantKwest, Inc.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

NOVEMBER 17, 2020

Located in Oss, the Netherlands, Lead Pharma is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for patients suffering from autoimmune diseases (a subset of immune-mediated diseases) and cancer. . The agreement encompasses Lead Pharma’s entire pipeline.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. About Dynavax.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

LifeSciVC

JULY 1, 2024

Try to create your own version of this heterodimer that synergistically brings your scientific interests together with a sense of societal responsibility. This heterodimer will bring more meaning to your work, enhance your productivity, and open doors over time. Build your social immunity. Don’t differentiate too quickly.

Science 86

Science Immune Response Molecular Biology RNA 86

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 27, 2020

The existing prototype has been created for influenza, but Professor Rob Field, co-founder of Iceni Diagnostics and a specialist in glycan science, claimed the product could be adapted to identity other pathogens such as coronavirus. Save your seat at IDBS’s upcoming webinar. Source link.

Virus 52

Virus Vaccine International Immune Response 52